| Literature DB >> 29150987 |
Xuehong Liu1,2, Yong Zhang1, Yang Yang2, Jingquan Lin1, Xue Huo2, Xiaoxue Du2, Benson O A Botchway2, Marong Fang2.
Abstract
In addition to imperiling an individual's daily life, spinal cord injury (SCI), a catastrophic medical damage, can permanently impair an individual's body function. Methylprednisolone (MP), a medically accepted therapeutic drug for SCI, is highly controversial for the lack of consensus on its true therapeutic effect. In recent years, curcumin has served as a potential and novel therapeutic drug in SCI. Our study was intended to investigate the precise effect of MP and curcumin in SCI. We examined the function of MP and curcumin in a SCI model rat, both in vivo and in vitro, and found that there was a momentous improvement in Basso-Beattie-Bresnahan scores in the MP-treated group when compared with Cur-treated group within 14 days. Results obtained from the histological, immunohistochemistry and ultrastructural examinations evidenced the curative effect of MP was better than curcumin before Day 14. Nonetheless, there was a significant variation in the treatment effect between the MP-treated and Cur-treated groups after 14 days. The curcumin's effectiveness was more obvious than MP after 14 days following SCI. As such, we surmise that curcumin has a better therapeutic potential than MP with a prolong treatment time in the wake of SCI. Anat Rec, 301:686-696, 2018.Entities:
Keywords: curcumin; methylprednisolone; spinal cord injury
Mesh:
Substances:
Year: 2017 PMID: 29150987 DOI: 10.1002/ar.23729
Source DB: PubMed Journal: Anat Rec (Hoboken) ISSN: 1932-8486 Impact factor: 2.064